AACR Special Conference in Cancer Research: Optimizing Therapeutic Efficacy and Tolerability through Cancer Chemistry
In Association with the AACR Chemistry in Cancer Research Working Group
December 9-11, 2024
Hilton Toronto
Toronto, Ontario, Canada
Conference cochairs
Philip Jones, The University of Texas MD Anderson Cancer Center, Houston, Texas
Angela N. Koehler, The Koch Institute at MIT, Cambridge, Massachusetts
Chudi O. Ndubaku, Paraza Pharma, Montreal, Québec City, Canada
Welcome to the AACR’s “Optimizing Therapeutic Efficacy and Tolerability Through Cancer Chemistry” conference, where Drs. Philip Jones, Angela N. Koehler, and Chudi O. Ndubaku, conference cochairs will convene leading cancer research and medicinal chemistry experts to explore groundbreaking cancer treatment approaches. This event is dedicated to advancing the design and development of therapeutic agents that offer enhanced efficacy and reduced toxicity, harnessing the latest in chemical biology and drug discovery to push the boundaries of cancer care.
The conference will feature plenary sessions on key topics, including creating safer therapeutic agents, the development of drugs with improved combinability, and cutting-edge nanoscale drug delivery systems. Attendees will also delve into the latest advancements in drug design and optimization, with a focus on emerging targets, brain penetration, and selective targeting for localized treatment. Join us for a focused exploration of how chemistry is shaping the future of cancer therapeutics.
